The development of drugs to treat some of the world’s most deadly viruses is a primary area of focus by the pharmaceutical community during the last 20 years.  There are dozens of antiviral drugs currently approved for use and many times more in development.  The ability to easily and quickly follow the impact of a given therapy on viral concentration provides significant advantages over traditional approaches that slow down the pace of research by days or weeks. To learn more, email us at


“We have basically stopped running plaque assays on our P0 and P1 virus stocks because the accuracy of the titers obtained with the Virus Counter leads to better virus amplifications than those obtained using plaque assay titers. The instrument saves one to two weeks on our virus production timeline and it is very helpful to know within a day or two that a transfection or co-transfection has yielded virus particles.”



Related Products